Caplyta (lumateperone) is not an SSRI. It is classified as an atypical antipsychotic, a fundamentally different type of medication. The confusion is understandable, though, because Caplyta does share one mechanism with SSRIs: it can block the serotonin reuptake transporter, the same protein that drugs like sertraline and fluoxetine target. But that’s only one piece of what Caplyta does, and it works through several other pathways that SSRIs don’t touch.
What Drug Class Caplyta Belongs To
Caplyta is FDA-approved as an atypical antipsychotic. It’s currently indicated for three conditions in adults: schizophrenia, depressive episodes associated with bipolar I or II disorder, and as an add-on to antidepressants for major depressive disorder (MDD). That last indication is likely why many people wonder whether it’s an SSRI, since it’s being prescribed alongside or in place of traditional antidepressants for depression.
Atypical antipsychotics are sometimes called “second-generation antipsychotics.” Other well-known drugs in this class include quetiapine (Seroquel), aripiprazole (Abilify), and olanzapine (Zyprexa). Like Caplyta, several of these are used for depression-related conditions, not just psychosis.
How Caplyta Works Differently From SSRIs
SSRIs do one main thing: they block the serotonin transporter, which prevents your brain from reabsorbing serotonin after it’s released. This leaves more serotonin available in the gaps between nerve cells, which gradually improves mood. That’s essentially their entire mechanism.
Caplyta takes a multi-target approach. Its strongest action is blocking a specific serotonin receptor called 5-HT2A. This is a completely different mechanism from boosting serotonin levels the way SSRIs do. On top of that, Caplyta modulates dopamine receptors, which is the hallmark of antipsychotic medications and something SSRIs don’t do at all.
Here’s where it gets interesting: Caplyta also inhibits the serotonin reuptake transporter, which is the exact mechanism SSRIs use. So it does have SSRI-like activity built into its pharmacology. This likely contributes to its antidepressant effects. But calling Caplyta an SSRI would be like calling a smartphone a calculator. Yes, it can do that job, but it does a lot more, and its primary function is different.
What Caplyta Is Approved to Treat
Caplyta has three FDA-approved uses:
- Schizophrenia in adults. This was its first approved indication.
- Bipolar depression in adults. It can be used alone or alongside mood stabilizers like lithium or valproate for depressive episodes in bipolar I or II disorder.
- Major depressive disorder in adults. It’s approved as an add-on therapy alongside an existing antidepressant, not as a standalone treatment for MDD.
In a Phase 3 trial for bipolar depression, patients taking Caplyta 42 mg daily showed significantly greater improvement in depression scores compared to placebo after six weeks, with an effect size of 0.56. That improvement was seen in both bipolar I and bipolar II patients.
Side Effects Compared to SSRIs
The side effect profile of Caplyta looks quite different from a typical SSRI. SSRIs are commonly associated with sexual dysfunction, nausea, insomnia, and weight changes. Caplyta’s most prominent side effect is drowsiness. In schizophrenia trials, 24% of patients on Caplyta experienced sleepiness or sedation, compared to 10% on placebo. In bipolar depression trials, that number was 13% versus 3%. Dry mouth, dizziness, and nausea also showed up more often than placebo, though at lower rates.
One area where Caplyta stands out among atypical antipsychotics is its metabolic profile. Many drugs in this class are associated with weight gain, increased blood sugar, and elevated cholesterol. In clinical trials, Caplyta’s effects on weight, fasting glucose, insulin, cholesterol, and triglycerides were similar to placebo across both schizophrenia and bipolar depression studies. The proportion of patients gaining 7% or more of their body weight was no different from placebo. For people who have struggled with weight gain on other psychiatric medications, this is a meaningful distinction.
Movement-related side effects, which are a concern with many antipsychotics, were also low in trials and occurred at rates similar to placebo.
Why the Confusion Makes Sense
If your doctor prescribed Caplyta for depression, it’s natural to assume it might be an antidepressant like an SSRI. The drug is heavily marketed for bipolar depression and MDD, and its commercials don’t emphasize the word “antipsychotic.” Many people associate antipsychotics with conditions like schizophrenia and don’t realize these medications are widely used for mood disorders too.
The fact that Caplyta genuinely does block serotonin reuptake adds another layer. It borrows a page from the SSRI playbook while also acting on dopamine and serotonin receptors in ways that SSRIs cannot. This combination of mechanisms is part of why it works for conditions that SSRIs alone may not adequately treat, like bipolar depression, where standard antidepressants can sometimes trigger manic episodes.
If you’re currently taking Caplyta or considering it, understanding that it’s an atypical antipsychotic with some SSRI-like properties helps set the right expectations for both its benefits and its side effects. Drowsiness rather than sexual dysfunction, minimal metabolic impact, and effectiveness across a broader range of conditions than a pure SSRI can offer.